Understanding how treat- ment responses evolve over time is essential for optimising therapeutic strategies in moderate- to-severe atopic dermatitis (AD). While clinical trials have demonstrated the efficacy of targeted therapies, real-world evidence describing longitu- dinal response trajectories remains limited. This study aimed to characterise temporal patterns of clinical response in patients with AD treated with dupilumab or upadacitinib in routine clinical practice.
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate‐to‐Severe Atopic Dermatitis: A Multicentre Real‐World Study: IL‐AD (Italian Landscape Atopic Dermatitis)
Giampiero Girolomoni;Martina Maurelli;
2026-01-01
Abstract
Understanding how treat- ment responses evolve over time is essential for optimising therapeutic strategies in moderate- to-severe atopic dermatitis (AD). While clinical trials have demonstrated the efficacy of targeted therapies, real-world evidence describing longitu- dinal response trajectories remains limited. This study aimed to characterise temporal patterns of clinical response in patients with AD treated with dupilumab or upadacitinib in routine clinical practice.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Potestio AD trajectories Derm Ther H 2026.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
452.05 kB
Formato
Adobe PDF
|
452.05 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
